Eisai and Biogen introduce LEQEMBI IQLIK for Alzheimer

Eisai Co., Ltd. and Biogen Inc. LEQEMBI® IQLIK™ (lecanemab-irmb) is now available in the U.S. It’s a subcutaneous injection for treating early Alzheimer’s disease (AD). It includes people with mild cognitive impairment (MCI) and mild dementia. This new option comes after an 18-month IV treatment with LEQEMBI. Patients can choose to keep their IV doses every four weeks or switch to a weekly 360 mg subcutaneous injection. They can use the LEQEMBI IQLIK autoinjector for this.

Eisai and Biogen have launched the LEQEMBI Companion™ program to support patients during treatment. This program offers various resources, such as:

• Educational support from nurse educators
• A welcome kit for care partners
• A digital platform created with Medisafe

These tools aim to help patients and their families navigate the journey.

The program helps patients by tracking injections. It teaches them how to administer at home. Patients can also get guidance on insurance and financial support. Eligible patients may also receive LEQEMBI at no cost through Eisai’s Patient Assistance Program (PAP).

こちらもお読みください： CM Plus launches “pharmo.AI” for pharma research support

LEQEMBI IQLIK lets you take treatment at home. This cuts down on time and reduces the need for infusion centers. It may also help healthcare resources become available for new patients. The therapy focuses on amyloid-beta protofibrils and plaques. These are key players in the neurodegenerative process of Alzheimer’s disease (AD). It aims to slow down disease progression by keeping its effects going after the first 18-month IV course.

Alzheimer’s disease leads to the buildup of amyloid plaques and tau tangles. These cause damage to neurons and result in cognitive decline. LEQEMBI targets both pathologies. Keep your brain sharp longer with LEQEMBI’s dual-action benefits.

LEQEMBI is indicated for patients with MCI or mild dementia due to Alzheimer’s disease. エーザイ handles global development and regulatory submissions. Meanwhile, Eisai and Biogen co-commercialize and promote the therapy in the U.S.